{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclosporins",
    "query": {
      "intervention": "Cyclosporins"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 539,
    "total_pages": 54,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclosporins&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T14:44:20.022Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00074269",
      "title": "Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "graft-versus-tumor induction therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2003-07",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074269"
    },
    {
      "nct_id": "NCT02904772",
      "title": "Alipogene Tiparvovec for the Treatment of LPLD Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "LPL Deficiency"
      ],
      "interventions": [
        {
          "name": "alipogene tiparvovec",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporins",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UniQure Biopharma B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-10",
      "completion_date": "2020-09",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02904772"
    },
    {
      "nct_id": "NCT00160355",
      "title": "Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wiskott-Aldrich Syndrome"
      ],
      "interventions": [
        {
          "name": "Hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Miltenyi CliniMACS selection system",
          "type": "DEVICE"
        },
        {
          "name": "Fludarabine, Melphalan, Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "Up to 18 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2005-05",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00160355"
    },
    {
      "nct_id": "NCT01998633",
      "title": "Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis",
        "Chronic Active Epstein-Barr Virus Infection",
        "Chronic Granulomatous Disease",
        "HIGM-1",
        "Leukocyte Adhesion Deficiency",
        "IPEX"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "4 Months to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2013-12",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01998633"
    },
    {
      "nct_id": "NCT00827255",
      "title": "Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Cyclosporine Ophthalmic Emulsion 0.05%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2009-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827255"
    },
    {
      "nct_id": "NCT04877288",
      "title": "A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Allograft Recipients"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine A",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Enteric Coated Mycophenolate Sodium",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 102,
      "start_date": "2021-07-21",
      "completion_date": "2034-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04877288"
    },
    {
      "nct_id": "NCT00639717",
      "title": "Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "stem cell transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "tacrolimus (standard GVHD prophylaxis)",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate (standard GVHD prophylaxis)",
          "type": "DRUG"
        },
        {
          "name": "etanercept",
          "type": "DRUG"
        },
        {
          "name": "methoxsalen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 48,
      "start_date": "2009-03",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00639717"
    },
    {
      "nct_id": "NCT00745420",
      "title": "Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "3 Years to 19 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-08",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00745420"
    },
    {
      "nct_id": "NCT06066957",
      "title": "Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "Transplant-Related Disorder"
      ],
      "interventions": [
        {
          "name": "Letermovir 480 MG [Prevymis]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2024-04-04",
      "completion_date": "2026-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06066957"
    },
    {
      "nct_id": "NCT01868360",
      "title": "Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Subconjunctival aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Standard of care only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Balamurali Ambati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-06",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-07",
      "last_synced_at": "2026-09-04T14:44:20.022Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868360"
    }
  ]
}